NCT02416492: A trial that was reported late by SanBio, Inc.
This trial has reported, although it was 263 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02416492 |
|---|---|
| Title | A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 6, 2016 |
| Completion date | Jan. 31, 2019 |
| Required reporting date | Jan. 31, 2020, midnight |
| Actual reporting date | Oct. 20, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 263 |